Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

565 Articles

Lee Jackson | Nov 13, 2014 at 9:15 AM EST

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand…

Paul Ausick | Oct 27, 2014 at 10:45 AM EDT

The 7 Most Heavily Shorted NYSE Stocks

Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held…

Lee Jackson | Oct 17, 2014 at 8:35 AM EDT

UBS’s Big List of Quality Stocks to Buy Now

UBS polled all of its analysts, who came up with 26 stocks by now. Here are the ones that offer…

Trey Thoelcke | Oct 10, 2014 at 7:20 AM EDT

Sprint Drops From the 5 Most Shorted NYSE Stocks

The most shorted stocks on the New York Stock Exchange at the September 30 settlement dates saw rising short interest…

Trey Thoelcke | Sep 25, 2014 at 7:55 AM EDT

AbbVie Joins the 5 Most Shorted NYSE Stocks

Short sellers shied away from Bank of American enough that it slipped out of the top five most shorted stocks…

Jon C. Ogg | Sep 23, 2014 at 1:30 PM EDT

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have…

Lee Jackson | Sep 15, 2014 at 10:55 AM EDT

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

A new research report from UBS focuses on four top companies that are making great strides in treatments for patients…

Trey Thoelcke | Sep 11, 2014 at 7:35 AM EDT

Sprint Joins the 5 Most Shorted NYSE Stocks

Surges in short interest between the August 15 and August 29 settlement dates pushed Sprint into the top five most…

Jon C. Ogg | Sep 3, 2014 at 2:10 PM EDT

Is Infinity Fully Valued Now, or Is More Upside Left?

Infinity Pharmaceuticals will partner with Abbvie to further develop and commercialize IPI-145, also known as Duvelisib.

Lee Jackson | Sep 3, 2014 at 10:45 AM EDT

Credit Suisse’s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of…

Paul Ausick | Jul 25, 2014 at 8:40 AM EDT

AbbVie Earnings Take Back Seat to Shire Merger

AbbVie reported better-than-expected second-quarter 2014 results before markets opened Friday morning, due in part to strong sales of its Humira…

Jon C. Ogg | Jul 2, 2014 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Apple, FireEye, JDSU Uniphase, Solar Stocks and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include…

Jon C. Ogg | Jun 2, 2014 at 8:55 AM EDT

Analyst Cancer and Biotech Stock Picks From ASCO

ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty…

Trey Thoelcke | May 22, 2014 at 8:20 AM EDT

Why You Buy Big Pharma If the Market Crashes

A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is…

Jon C. Ogg | May 7, 2014 at 8:25 AM EDT

Top Analyst Upgrades and Downgrades: eBay, GNC, Groupon, Hecla, J.C. Penney, Whole Foods and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Wednesday, May 7, 2014. They include eBay, GNC,…

1 … 34 35 36 37 38

AbbVie : ABBV

All AbbVie Articles

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

The 7 Most Heavily Shorted NYSE Stocks

UBS’s Big List of Quality Stocks to Buy Now

Sprint Drops From the 5 Most Shorted NYSE Stocks

AbbVie Joins the 5 Most Shorted NYSE Stocks

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Sprint Joins the 5 Most Shorted NYSE Stocks

Is Infinity Fully Valued Now, or Is More Upside Left?

Credit Suisse’s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

AbbVie Earnings Take Back Seat to Shire Merger

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Apple, FireEye, JDSU Uniphase, Solar Stocks and More

Analyst Cancer and Biotech Stock Picks From ASCO

Why You Buy Big Pharma If the Market Crashes

Top Analyst Upgrades and Downgrades: eBay, GNC, Groupon, Hecla, J.C. Penney, Whole Foods and More

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

AbbVie : ABBV

All AbbVie Articles

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

The 7 Most Heavily Shorted NYSE Stocks

UBS’s Big List of Quality Stocks to Buy Now

Sprint Drops From the 5 Most Shorted NYSE Stocks

AbbVie Joins the 5 Most Shorted NYSE Stocks

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Sprint Joins the 5 Most Shorted NYSE Stocks

Is Infinity Fully Valued Now, or Is More Upside Left?

Credit Suisse’s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

AbbVie Earnings Take Back Seat to Shire Merger

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Apple, FireEye, JDSU Uniphase, Solar Stocks and More

Analyst Cancer and Biotech Stock Picks From ASCO

Why You Buy Big Pharma If the Market Crashes

Top Analyst Upgrades and Downgrades: eBay, GNC, Groupon, Hecla, J.C. Penney, Whole Foods and More

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026